The future of small molecule inhibitors in lymphoma Journal Article
| Author: | Gerecitano, J. |
| Article Title: | The future of small molecule inhibitors in lymphoma |
| Abstract: | For the many patients with lymphoma that has relapsed after and/or has become refractory to existing treatments, the development of novel therapeutics is imperative. Investigation into intracellular processes that are dysregulated during lymphomagenesis has uncovered several new potential targets for anticancer agents. Although monoclonal antibodies and other immunotherapeutics have led to dramatic advances in the treatment of patients with lymphoma, the parallel development of small molecule inhibitors has been equally exciting. These agents, whose small size allows direct entry into tumor cells, can target distinct proteins or complexes, thereby disrupting molecular processes on which neoplastic cells depend for survival and growth. This review surveys the published literature on many of these new targeted molecules, focusing on some of the most promising agents for which phase 2 data currently exist. It also explores the potential for incorporating these agents into broader multidrug regimens. © Current Medicine Group, LLC 2009. |
| Keywords: | signal transduction; unclassified drug; histone deacetylase inhibitor; prednisone; clinical trial; drug tolerability; fatigue; neutropenia; review; doxorubicin; diarrhea; drug dose reduction; drug efficacy; drug safety; side effect; antineoplastic agents; rituximab; antineoplastic agent; cell survival; protein bcl 2; apoptosis; bortezomib; proteasome inhibitor; mantle cell lymphoma; multiple myeloma; boronic acids; protease inhibitors; pyrazines; anemia; protein degradation; gastrointestinal symptom; neuropathy; thrombocytopenia; cyclophosphamide; dexamethasone; vincristine; antineoplastic activity; continuous infusion; cytotoxicity; drug discovery; hodgkin disease; deforolimus; temsirolimus; hyperglycemia; gastrointestinal toxicity; cutaneous t cell lymphoma; t cell lymphoma; nonhodgkin lymphoma; transcription regulation; lymphoma; vorinostat; cell cycle arrest; forecasting; down regulation; upregulation; liver function test; hypercholesterolemia; somnolence; mammalian target of rapamycin inhibitor; chronic lymphatic leukemia; oligopeptides; abt 263; everolimus; kinesin spindle protein inhibitor; n (2 aminophenyl) 4 [4 (3 pyridinyl) 2 pyrimidinylaminomethyl]benzamide; obatoclax; oblimersen; panobinostat; pr 171; protein bcl 2 inhibitor; romidepsin; salinosporamide a; euphoria; follicular lymphoma; marginal zone lymphoma; megakaryocyte; histone deacetylases; proto-oncogene proteins c-bcl-2 |
| Journal Title: | Current Oncology Reports |
| Volume: | 11 |
| Issue: | 5 |
| ISSN: | 1523-3790 |
| Publisher: | Springer |
| Date Published: | 2009-09-01 |
| Start Page: | 378 |
| End Page: | 385 |
| Language: | English |
| DOI: | 10.1007/s11912-009-0051-1 |
| PUBMED: | 19679013 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Export Date: 30 November 2010" - "CODEN: CORUA" - "Source: Scopus" |
